Weight-Loss drug may curb alcohol cravings in fatty liver patients
NCT ID NCT06546384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether semaglutide (a GLP-1 drug used for diabetes and weight loss) can help people with obesity and fatty liver disease reduce or stop drinking alcohol. 64 participants will receive either semaglutide injections plus lifestyle counseling, or counseling alone. The main goal is to see if more people in the drug group achieve total alcohol abstinence after 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide
- What this could lead to
- If it works, this could point toward a new way to help people with obesity and fatty liver cut down on alcohol.
- What could go wrong
- This is a small, early-stage trial with only 64 people. It may not show a clear benefit, and semaglutide can cause nausea and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADIPOSITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Bern
Bern, 3010, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a brain zapping headset curb relapse in addiction?
- Wine grape leftovers could be a Heart-Healthy superfood
- Can a smartphone app tame Alcohol-Related liver disease?
- Calm in a room: can sensory therapy soothe the mind?
- HIV and fatty liver: a hidden link under the microscope
- Can a brief alcohol intervention improve mental health treatment?